Neumora Therapeutics (NMRA) Other Operating Expenses (2023 - 2025)
Neumora Therapeutics' (NMRA) quarterly Other Operating Expenses came in at $5.0 million in Q3 2025, down 92.18% quarter-over-quarter from $63.9 million in Q4 2023.
Neumora Therapeutics (NMRA) Other Operating Expenses (2023 - 2025) Analysis & Trends
Neumora Therapeutics' Other Operating Expenses history runs 2 years deep, the most recent figure standing at $5.0 million for Q3 2025.
- On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $5.0 million in Q3 2025; TTM through Mar 2026 was $5.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.0 million, changed N/A from the prior year.
- Other Operating Expenses declined to $5.0 million in Q3 2025 per NMRA's latest filing, from $63.9 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $63.9 million in Q4 2023 and bottomed at $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Neumora Therapeutics | 270.71 Mn | 270.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.00 Mn |
| Dec 31, 2023 | 63.90 Mn |